Skip to content
WeighLab
Menu
Ranked #352 · Grade C

Bioverse review

Bioverse (GoBioverse) offers compounded semaglutide and tirzepatide plus brand-name Ozempic, Wegovy, and Mounjaro.

Visit Bioverse Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$129/mo (starting dose, compounded)
Tirzepatide
$399/mo (starting dose, compounded)
Coverage
Coverage not published
Brand-name
Yes

Semaglutide · modeled / year

$1,548

Tirzepatide · modeled / year

$4,788

The Index scorecard

Bioverse scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month68/100
Price Transparency30/100
Nationwide Access24/100
Formulation Options79/100
Clinical Oversight74/100
Contract Flexibility33/100

Where the value is

  • Wide formulary — compounded and brand-name semaglutide + tirzepatide plus metformin
  • No membership, cancellation, doctor, or hidden fees
  • Uses US-licensed, FDA-regulated pharmacies

The tradeoffs

  • No visible LegitScript or PCAB accreditation
  • State availability not disclosed beyond 'a provider licensed in your state'
  • Broader longevity platform (NAD+, B12, glutathione, hair, skincare, heart health) rather than GLP-1 focused

The bottom line

Best for: Cost-first shoppers who want broad GLP-1 formulary with longevity add-ons. Bioverse (GoBioverse) offers compounded semaglutide and tirzepatide plus brand-name Ozempic, Wegovy, and Mounjaro.

Ranked #352 of 492 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 491 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Bioverse.

The 18 programs nearest this one

Pricing, states and verification reflect Bioverse's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Bioverse's site. Not medical advice; see our disclosure.

← Back to the value leaderboard